Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

BI and ViraTherapeutics collaborate for oncolytic virus platform; BI has option to acquire ViraTherapeutics; option exercised

28 Oct 2021

Executive Summary

Boehringer Ingelheim Pharmaceuticals Inc. entered into a collaboration with ViraTherapeutics GMBH to develop a next generation oncolytic virus platform based on ViraTherapeutics' lead candidate VSV-GP (Vesicular Stomatitis Virus glycoprotein) currently in preclinical development for solid cancers.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Immuno-Oncology
Deal Status
  • Concluded
Deal Type
  • Alliance
    • Includes M&A Option
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By